BCM
GILD icon

Brookmont Capital Management’s Gilead Sciences GILD Stock Holding History

Brookmont Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.78M Buy
37,837
+140
+0.4% +$18.4K 2.56% 7
2026
Q1 		$5.25M Buy
37,697
+1,104
+3% +$155K 2.94% 4
2025
Q4 		$4.49M Sell
36,593
-52
-0.1% -$6.32K 2.6% 6
2025
Q3 		$4.07M Sell
36,645
-906
-2% -$103K 2.26% 10
2025
Q2 		$4.16M Sell
37,551
-940
-2% -$100K 2.39% 9
2025
Q1 		$4.31M Sell
38,491
-12,592
-25% -$1.3M 2.43% 8
2024
Q4 		$4.72M Buy
51,083
+7,322
+17% +$659K 2.52% 8
2024
Q3 		$3.67M Sell
43,761
-1,435
-3% -$109K 1.89% 16
2024
Q2 		$3.1M Sell
45,196
-1,488
-3% -$99.3K 1.7% 21
2024
Q1 		$3.42M Buy
46,684
+1,005
+2% +$77.3K 1.8% 20
2023
Q4 		$3.7M Sell
45,679
-812
-2% -$63.2K 2.07% 16
2023
Q3 		$3.48M Sell
46,491
-326
-0.7% -$25.1K 2.17% 16
2023
Q2 		$3.61M Buy
46,817
+25
+0.1% +$1.99K 2.18% 16
2023
Q1 		$3.88M Buy
46,792
+212
+0.5% +$17.6K 2.44% 11
2022
Q4 		$4M Buy
46,580
+17,238
+59% +$1.37M 2.46% 9
2022
Q3 		$1.81M Buy
29,342
+2,346
+9% +$148K 1.26% 30
2022
Q2 		$1.67M Buy
26,996
+351
+1% +$21.7K 1.15% 30
2022
Q1 		$1.58M Buy
26,645
+571
+2% +$36.5K 0.95% 32
2021
Q4 		$1.89M Sell
26,074
-1,104
-4% -$76K 1% 30
2021
Q3 		$1.9M Buy
27,178
+514
+2% +$36.1K 1.12% 31
2021
Q2 		$1.84M Buy
26,664
+18
+0.1% +$1.2K 1.11% 30
2021
Q1 		$1.72M Buy
26,646
+180
+0.7% +$11.6K 1.11% 30
2020
Q4 		$1.54M Sell
26,466
-1,670
-6% -$101K 1.09% 29
2020
Q3 		$1.78M Buy
28,136
+518
+2% +$35.9K 1.32% 24
2020
Q2 		$2.13M Sell
27,618
-11,164
-29% -$856K 1.7% 22
2020
Q1 		$2.9M Buy
38,782
+3,225
+9% +$223K 2.34% 11
2019
Q4 		$2.31M Sell
35,557
-2,940
-8% -$191K 1.38% 28
2019
Q3 		$2.44M Sell
38,497
-125
-0.3% -$8.17K 1.39% 28
2019
Q2 		$2.61M Buy
38,622
+195
+0.5% +$12.8K 1.57% 25
2019
Q1 		$2.5M Buy
38,427
+81
+0.2% +$5.38K 1.54% 26
2018
Q4 		$2.4M Buy
38,346
+451
+1% +$31.5K 1.63% 28
2018
Q3 		$2.93M Buy
37,895
+41
+0.1% +$3.1K 1.74% 23
2018
Q2 		$2.68M Buy
37,854
+4,327
+13% +$306K 1.69% 25
2018
Q1 		$2.53M Sell
33,527
-31,387
-48% -$2.5M 1.67% 26
2017
Q4 		$4.65M Buy
64,914
+21,628
+50% +$1.64M 2% 29
2017
Q3 		$3.51M Buy
43,286
+51
+0.1% +$3.9K 1.92% 26
2017
Q2 		$3.06M Buy
43,235
+5,154
+14% +$343K 1.15% 30
2017
Q1 		$2.59M Buy
+38,081
New +$2.68M 0.96% 32

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Brookmont Capital Management's GILD Position: Q2 2026 in Review

Brookmont Capital Management increased its Gilead Sciences (GILD) stake by 0.37% in Q2 2026, buying an estimated $18.4K and bringing the position to 37,837 shares worth $4.78M. The position accounts for 2.56% of the portfolio, ranked #7.

Brookmont Capital Management first reported a position in GILD in Q1 2017 and has held it in 38 quarters since. The position peaked at $5.25M in Q1 2026. 682 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Brookmont Capital Management held 37,837 shares of Gilead Sciences worth $4.78M as of Q2 2026.
  • Brookmont Capital Management bought 140 Gilead Sciences shares in Q2 2026, an estimated $18.4K.
  • Gilead Sciences made up 2.56% of Brookmont Capital Management's portfolio in Q2 2026, its #7 holding.
  • Brookmont Capital Management first reported a position in Gilead Sciences in Q1 2017 and has held it in 38 quarters since.
  • Brookmont Capital Management's Gilead Sciences position peaked at $5.25M in Q1 2026.
  • 682 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Brookmont Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.